| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9db46a32349ce4b203970a1fe9d0d01 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bd37c4405c27e0989bfe8f09930cf17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4fe8e05545aa0651d0e128de9b2c68c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4f747ab7b8763a5ee7a71f89b353944
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea627b0eeb1dd8e10406355fd412a36c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_347c8b3726716314d488479e9c068086 |
| publicationDate |
2021-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113366018-A |
| titleOfInvention |
CLEC12AxCD3 bispecific antibodies and methods for treating disease |
| abstract |
The present invention relates to means and methods for treating CLEC 12A-positive cancer in an individual. In some embodiments, the method comprises treating an individual in need thereof with two or more administrations of a bispecific antibody that binds CDS and CLEC12A, wherein a first amount of the bispecific antibody is administered in a first administration and wherein the amount of the bispecific antibody in each subsequent administration is higher than the amount of the bispecific antibody in the first administration. In some embodiments, a dosing regimen that provides CLEC 12A-positive cancer treatment at intervals and retains hematopoietic stem cell compartments allows for the recovery of normal CLEC 12A-positive hematopoietic cells. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |